AK 002

Drug Profile

AK 002

Alternative Names: AK002

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer Allakos
  • Class Anti-inflammatories; Antiallergics; Antibodies; Antifibrotics; Eye disorder therapies; Food allergy immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Mast cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Eosinophilic gastroenteritis; Urticaria
  • Phase I/II Peanut hypersensitivity
  • Phase I Conjunctivitis; Keratoconjunctivitis; Systemic mastocytosis
  • Preclinical Fibrosis

Most Recent Events

  • 02 Jun 2018 Preclinical data for Eosinophilic gastroenteritis presented at the Digestive Disease Week 2018 (DDW-2018)
  • 16 May 2018 Phase-I/II clinical trials in Peanut hypersensitivity in Denmark (IV) (EudraCT2018-000165-36)
  • 12 Apr 2018 Allakos plans a phase II ENIGMA trial for Eosinophilic Gastroenteritis in USA (NCT03496571)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top